Skip to main content
Premium Trial:

Request an Annual Quote

DNA Script Awarded $5.5M in Grant Funding

NEW YORK (GenomeWeb) – DNA Script announced today that it has been awarded $5.5 million in grant funding from the European Commission and French investment bank Bpifrance.

DNA Script manufactures synthetic DNA and RNA using a proprietary enzymatic technology and nucleotide chemistry. Earlier this year, it acquired an exclusive license to a novel DNA building block for use in enzymatic DNA synthesis from Dynamic Combinatorial Chemistry.

According to Paris-based DNA Script, the grant money will be provided in the form of subsidies and refundable advances through the EC's Horizon 2020 European Innovation Council program and Bpifrance's innovation development programs.

"We are excited about recent breakthroughs we have made with our technology platform, and these additional resources will allow us to further accelerate the development of the company," DNA Script Cofounder and CEO Thomas Ybert said in a statement.

The grants follow a Series A financing round led by Illumina Ventures, in which DNA Script raised €11 million ($13.5 million). It said it has raised a total of $24 million to date.

The Scan

Team Tracks Down Potential Blood Plasma Markers Linked to Heart Failure in Atrial Fibrillation Patients

Researchers in BMC Genomics found 10 differentially expressed proteins or metabolites that marked atrial fibrillation with heart failure cases.

Study Points to Synonymous Mutation Effects on E. Coli Enzyme Activity

Researchers in Nature Chemistry saw signs of enzyme activity shifts in the presence of synonymous mutations in a multiscale modeling analysis of three Escherichia coli genes.

Team Outlines Paternal Sample-Free Single-Gene Approach for Non-Invasive Prenatal Screening

With data for nearly 9,200 pregnant individuals, researchers in Genetics in Medicine demonstrate the feasibility of their carrier screening and reflex single-gene non-invasive prenatal screening approach.

Germline-Targeting HIV Vaccine Shows Promise in Phase I Trial

A National Institutes of Health-led team reports in Science that a broadly neutralizing antibody HIV vaccine induced bnAb precursors in 97 percent of those given the vaccine.